Quince Therapeutics, Inc.
QNCX
$1.05
$0.05956.01%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -126.84% | 80.19% | -148.71% | -25.35% | -66.21% |
| Total Depreciation and Amortization | -81.40% | 95.45% | 10.00% | -86.84% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 275.97% | -108.36% | 471.97% | 57.43% | 269.61% |
| Change in Net Operating Assets | 1,346.71% | 89.31% | -76.65% | -422.00% | 416.46% |
| Cash from Operations | -4.02% | 16.92% | -4.62% | -37.43% | -26.15% |
| Capital Expenditure | -189.13% | -17.95% | 0.00% | -62.50% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 53.82% | 244.79% | -155.17% | 18.90% | 107.15% |
| Cash from Investing | 52.95% | 242.73% | -155.84% | 65.38% | 48.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -81.58% | 233.33% | 470.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | 100.00% | -14,385.71% | -81.58% | 233.33% | 470.00% |
| Foreign Exchange rate Adjustments | 470.00% | 75.10% | -177.74% | 224.50% | -260.65% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 167.82% | 62.54% | -1,412.25% | 220.57% | 13.56% |